$12.65
1.56% yesterday
Nasdaq, Apr 04, 10:00 pm CET
ISIN
US2681582019
Symbol
DVAX

Dynavax Technologies Corporation Stock News

Neutral
PRNewsWire
one day ago
Dynavax's Board is Overseeing Record Operational and Financial Performance Outlines Extensive Engagement with Deep Track and Multiple Attempts to Reach a Resolution EMERYVILLE, Calif. , April 3, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) ("Dynavax" or the "Company"), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today ...
Neutral
Business Wire
26 days ago
GREENWICH, Conn.--(BUSINESS WIRE)--Deep Track Capital, LP, (together with its affiliates, “Deep Track” or “we”), one of the largest shareholders of Dynavax Technologies Corporation (NASDAQ: DVAX) (“Dynavax”, “DVAX” or the “Company”), with ownership of approximately 14.34% of the Company's outstanding shares, today sent a letter to the Company's Board of Directors (the “Board”) related to Deep T...
Neutral
PRNewsWire
30 days ago
Opportunistic refinancing extends the maturity of most of existing debt with improved terms and reduces dilution to existing capital structure $225 million of convertible notes due in 2030 issued, including an exchange for the retirement of ~$185 million of existing convertible notes due in 2026 and ~$40 million of new money Dynavax repurchased ~$8 million of the Company's common stock in conne...
Positive
Seeking Alpha
about one month ago
Dynavax Technologies posted solid Q4 results and FY 2025 guidance late in February, with Heplisav-B driving revenue growth and profitability. Heplisav-B's market share continues to grow due to its superior efficacy and compliance compared to previous hepatitis B vaccines. Heplisav-B should eventually garner 60% of a market that is predicted to grow to $900 million in the U.S. by 2030.
Neutral
PRNewsWire
about one month ago
EMERYVILLE, Calif. , Feb. 25, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that the Company will participate in the following upcoming investor conferences: TD Cowen 45th Annual Healthcare Conference on Tuesday, March 4 at 1:10 p.m.
Neutral
Seeking Alpha
about one month ago
Dynavax Technologies Corporation (NASDAQ:DVAX ) Q4 2024 Earnings Conference Call February 20, 2025 4:30 PM ET Company Participants Paul Cox - Vice President, Investor Relations & Corporate Communications Ryan Spencer - Chief Executive Officer Donn Casale - Chief Commercial Officer Rob Janssen - Chief Medical Officer Kelly MacDonald - Chief Financial Officer Conference Call Participants Matt Phi...
Neutral
PRNewsWire
about one month ago
HEPLISAV-B® 2024 net product revenue grew 26% year-over-year to $268 million; net product revenue expected to be $305 to $325 million in 2025 Top-line results in Phase 1/2 shingles trial expected in Q3 2025 Plan to initiate Phase 2 trial for plague vaccine in Q3 2025 Expect completion of $200 million share repurchase program in 2025 Conference call today at 4:30 p.m. ET/1:30 p.m.
Neutral
PRNewsWire
about one month ago
Reiterates Meaningful Board Change Already Underway EMERYVILLE, Calif. , Feb. 19, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) ("Dynavax" or the "Company"), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today issued a statement underscoring continued execution momentum and commitment to driving long-term stockholder value.

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today